Study:
Phase II Trial of Triple Receptor Tyrosine Kinase Receptor Inhibitor BIBF 1120 in Recurrent High-Grade Gliomas
Rationale:
n/a
Purpose:
BIBF 1120 is a newly discovered compound that may stop cancer cells from growing abnormally.
This drug is currently being used in treatment for other cancers in research studies and
information from those other research studies suggests that this agent, BIBF 1120, may help
to stop recurrent malignant glioma cells from multiplying and it may also prevent the growth
of new blood vessels at the site of the tumor. In this research study, the investigators
are looking to see how well BIBF 1120 works in patients with recurrent malignant gliomas.
Study Status: Active, not recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
Glioblastoma
Gliosarcoma
Anaplastic Astrocytoma
Anaplastic Oligodendroglioma
Anaplastic Oligoastrocytoma |
Drug: BIBF 1120 |
Phase 2 |
Verified by
Patrick Y. Wen, MD
March, 2013
Sponsored by: Patrick Y. Wen, MD
Information provided by: Dana-Farber Cancer Institute
ClinicalTrials.gov identifier: NCT01380782
Study Type: Interventional
Study Design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic
Cleveland, Ohio 44195
United States
Patrick Y Wen, M.D.., Principal Investigator